Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells
Open Access
- 25 February 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 739976
Abstract
Multiple myeloma (MM) is still an incurable plasma cell tumor. Natural killer (NK) cells are characterized by efficient anti-tumor activity, and their activity is one basis of cancer immunotherapeutic strategies. Tim-3, one of the immune checkpoint molecules, negatively regulates NK cell activity. To evaluate roles of the Tim-3 pathway blocking in the regulation of NK cell mediated- anti-MM activity in vitro and in vivo, anti-Tim-3 and/or anti-its ligand (HMGB1, CEACAM1 or Galetin-9) antibodies were applied respectively to block the Tim-3 pathway in the present study. Our results showed that Tim-3 was highly expressed on NK cells, in particular on in vitro expanded NK (exNK) cells. NK cells with Tim-3 blockade displayed a significantly higher degranulation and cytolytic activity against both human MM cell lines and primary MM cells, compared to the isotype control antibody-treated NK cells. The increased NK cell cytolytic activity by Tim-3 blocking was associated with up-regulation of cytotoxicity-related molecules, including perforin, granzyme B, TNF-α and IFN-γ. Ligand (HMGB1, CEACAM1 or Galetin-9) expression on MM cells was at different levels, and accordingly, the improvement in NK cell-mediated killing activity by different ligand blocking were also varying. Tim-3 blocking showed much more efficient enhancement of NK cell cytolytic activity than its ligand blockings. More importantly, exNK cells with Tim-3 blockade significantly inhibited MM tumor growth and prolonged the survival of MM-bearing NOD/SCID mice. Our results also showed that NK cells from peripheral blood and bone marrow of MM patients expressed much higher levels of Tim-3 than their counterparts from controls. Taken together, Tim-3 may be an important target molecule used for developing an antibody and/or NK cell based immunotherapeutic strategies for MM.Keywords
This publication has 34 references indexed in Scilit:
- Tim-3: An Emerging Target in the Cancer Immunotherapy LandscapeCancer Immunology Research, 2014
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 BlockadeCancer Immunology Research, 2014
- Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathyImmunology, 2013
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicityBlood, 2012
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinomaHepatology, 2012
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer ProgressionPLOS ONE, 2012
- siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functionsGene Therapy, 2011
- Treatment of multiple myelomaNature Reviews Clinical Oncology, 2011
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem CellsCell Stem Cell, 2010
- Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma2004